Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus JUNEL 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus JUNEL 1 5 30.
ENSKYCE vs JUNEL 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive